Vimarsana
Biggest News Aggregation in the World

Page 18 - Adaptive Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Adaptive Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Adaptive Research Today - Breaking & Trending Today

Kintara Therapeutics Inc ends fiscal third quarter with cash and cash equivalents of about $15.7 million - Vimarsana News

Kintara Therapeutics Inc ends fiscal third quarter with cash and cash equivalents of about $15.7 million

Kintara Therapeutics ends fiscal 3Q with cash and cash equivalents of about $15.7M The capital runway is expected to be sufficient to fund the company's planned operations to the second quarter of calendar year 2022 Kintara achieved the healthy cash stockpile primarily due to the exercise of warrants as well as operational and resource synergies realized through the Adgero Biopharmaceuticals merger in August 2020 Kintara Therapeutics Inc (NASDAQ:KTRA), which is focused on the development of new solid tumor cancer therapies, said it closed its fiscal third quarter with cash and cas...

Kintara Presents Updates on Two Phase 2 Clinical Trials at the 2021 American Association for Cancer Research Annual Meeting - Vimarsana News

Kintara Presents Updates on Two Phase 2 Clinical Trials at the 2021 American Association for Cancer Research Annual Meeting

Kintara Presents Updates on Two Phase 2 Clinical Trials at the 2021 American Association for Cancer Research Annual Meeting News provided by Share this article Share this article SAN DIEGO, April 12, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, or resistant to, current treatment regimens, today announced interim data results from two Phase 2 clinical trials evaluating VAL-083, the Company's lead compound, for the treatment of glioblastoma multiforme (GB...

Henry Ford Cancer Institute is First in the World to Activate Two New Treatments in GBM AGILE Trial for Glioblastoma Brain Cancer - Vimarsana News

Henry Ford Cancer Institute is First in the World to Activate Two New Treatments in GBM AGILE Trial for Glioblastoma Brain Cancer

 at Henry Ford Health System . “Through global collaboration, GBM AGILE is making it possible for some of the world’s foremost experts in glioblastoma research and treatment to collaborate and advance the pace at which scientific and clinical breakthroughs can be achieved.” After opening at Henry Ford Cancer Institute, the two new interventions –   VAL-083   from Kintara Therapeutics, Inc.  and   paxalisib   from Kazia Therapeutics Limited– will subsequently open at more than 35 trial sites across the United States, with additional global sites in Canada, Europe and ...

Henry Ford Health System First in World to Test Treatments for Brain Cancer - Vimarsana News

Henry Ford Health System First in World to Test Treatments for Brain Cancer

DBusiness Magazine Henry Ford Health System First in World to Test Treatments for Brain Cancer Detroit-based Henry Ford Cancer Institute has announced it is the first site in the world to activate two treatments for glioblastoma, the deadliest form of brain cancer, as part of a patient-centered adaptive platform trial called GBM AGILE. Henry Ford Cancer Institute is the first on the planet to active two treatments for the deadliest form of brain cancer. // Photo courtesy of Henry Ford Health System Detroit-based Henry Ford Cancer Institute has announced it is the first site in the world to ac...

Henry Ford Cancer Institute first-in-world to activate new treatments in GBM AGILE Trial - Vimarsana News

Henry Ford Cancer Institute first-in-world to activate new treatments in GBM AGILE Trial

 E-Mail IMAGE: Tom Mikkelsen, M.D., principal investigator for GBM AGILE at Henry Ford Cancer Institute, and medical director of the Precision Medicine Program and Clinical Trials Office at Henry Ford Health System.... view more  Credit: Henry Ford Health System DETROIT (Feb. 3, 2021) - Henry Ford Cancer Institute is the first site in the world to activate two new treatments for glioblastoma (GBM), the deadliest form of brain cancer, as part of a patient-centered adaptive platform trial known as GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment). Led by Global ...